TritonPoint Wealth’s Vertex Pharmaceuticals VRTX Stock Holding History

TritonPoint Wealth’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$437K	Sell	835 -24	-3%	-$12.3K	0.04%	196
2026 Q2	$427K	Buy	859 +247	+40%	+$109K	0.04%	198
2026 Q1	$273K	Buy	612 +95	+18%	+$44.3K	0.03%	228
2025 Q4	$234K	Sell	517 -31	-6%	-$13.4K	0.02%	245
2025 Q3	$215K	Sell	548 -53	-9%	-$22.2K	0.02%	334
2025 Q2	$268K	Sell	601 -3	-0.5%	-$1.38K	0.02%	293
2025 Q1	$293K	Buy	604 +83	+16%	+$38.7K	0.03%	280
2024 Q4	$210K	Sell	521 -7	-1%	-$3.24K	0.02%	323
2024 Q3	$244K	Buy	528 +35	+7%	+$16.8K	0.02%	301
2024 Q2	$231K	Buy	+493	New	+$214K	0.02%	295

Other funds holding VRTX

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $194B AUM 32.2% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

TritonPoint Wealth's VRTX Position: Q3 2026 in Review

TritonPoint Wealth reduced its Vertex Pharmaceuticals (VRTX) stake by 2.8% in Q3 2026, selling an estimated $12.3K and leaving 835 shares worth $437K. The position accounts for 0.04% of the portfolio, ranked #196.

TritonPoint Wealth first reported a position in VRTX in Q2 2024 and has held it in 10 quarters since. 972 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

TritonPoint Wealth held 835 shares of Vertex Pharmaceuticals worth $437K as of Q3 2026.
TritonPoint Wealth sold 24 Vertex Pharmaceuticals shares in Q3 2026, an estimated $12.3K.
Vertex Pharmaceuticals made up 0.04% of TritonPoint Wealth's portfolio in Q3 2026, its #196 holding.
TritonPoint Wealth first reported a position in Vertex Pharmaceuticals in Q2 2024 and has held it in 10 quarters since.
972 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on TritonPoint Wealth's 13F filing for Q3 2026, filed 19 Oct 2026.